Takeda-backed Ascentage Pharma Group (AAPG) (OTCPK:ASPHF), which is developing treatments for blood cancer, has set terms for a $170M U.S. initial public offering. In an SEC filing, Ascentage (AAPG) ...
Some results have been hidden because they may be inaccessible to you